Formulation development of the C34 adjuvant for glycolipid-based antigens to increase the vaccine efficacy. Glycolipid antigens, such as Globo H (GH), have been found to be overexpressed (ultimately 80%) in a variety of cancers, such as breast, prostate and lung cancers. C34 is an α-galactosylceramide analog with the ability to enhance the GH-mediated immune response. Currently, we are working on the process development and optimization of the C34 solution formulation.